Schwab Charles Investment Management Inc. increased its stake in Cerus Corporation (NASDAQ:CERS) by 6.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 439,172 shares of the biotechnology company’s stock after buying an additional 25,530 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.42% of Cerus Corporation worth $1,955,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Teachers Advisors LLC raised its position in Cerus Corporation by 0.4% in the fourth quarter. Teachers Advisors LLC now owns 269,964 shares of the biotechnology company’s stock valued at $1,174,000 after buying an additional 1,152 shares in the last quarter. Stephens Inc. AR raised its position in Cerus Corporation by 0.3% in the first quarter. Stephens Inc. AR now owns 950,729 shares of the biotechnology company’s stock valued at $4,231,000 after buying an additional 2,539 shares in the last quarter. American International Group Inc. raised its position in Cerus Corporation by 7.1% in the first quarter. American International Group Inc. now owns 62,374 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 4,127 shares in the last quarter. Marathon Capital Management raised its position in Cerus Corporation by 32.4% in the first quarter. Marathon Capital Management now owns 24,500 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 6,000 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Cerus Corporation by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 505,652 shares of the biotechnology company’s stock valued at $2,250,000 after buying an additional 6,710 shares in the last quarter. Hedge funds and other institutional investors own 62.58% of the company’s stock.
Shares of Cerus Corporation (CERS) traded down 3.061% during mid-day trading on Friday, hitting $2.375. The stock had a trading volume of 206,082 shares. The stock’s 50-day moving average price is $2.36 and its 200 day moving average price is $3.26. Cerus Corporation has a 1-year low of $1.93 and a 1-year high of $7.19. The company’s market capitalization is $259.20 million.
Cerus Corporation (NASDAQ:CERS) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $9.53 million for the quarter, compared to analysts’ expectations of $9.14 million. Cerus Corporation had a negative return on equity of 120.31% and a negative net margin of 164.39%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.18) EPS. On average, analysts predict that Cerus Corporation will post ($0.68) EPS for the current fiscal year.
A number of analysts have recently weighed in on CERS shares. BidaskClub lowered Cerus Corporation from a “hold” rating to a “sell” rating in a research note on Friday. Cantor Fitzgerald restated a “buy” rating and issued a $7.00 target price on shares of Cerus Corporation in a research note on Wednesday, June 7th. ValuEngine lowered Cerus Corporation from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 17th. Zacks Investment Research lowered Cerus Corporation from a “hold” rating to a “sell” rating in a research note on Friday, May 26th. Finally, BTIG Research restated a “buy” rating and issued a $5.00 target price on shares of Cerus Corporation in a research note on Sunday, May 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Cerus Corporation presently has a consensus rating of “Hold” and an average price target of $7.25.
In other Cerus Corporation news, insider Laurence M. Corash acquired 92,796 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were acquired at an average cost of $2.45 per share, with a total value of $227,350.20. Following the transaction, the insider now owns 1,375,711 shares of the company’s stock, valued at approximately $3,370,491.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.40% of the company’s stock.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Corporation (NASDAQ:CERS).
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
